



5 May 2020

**NZX/ASX Code: EBO**


**Macquarie Australia Conference Presentation**

Please see attached a copy of a presentation to be delivered at the Macquarie Australia Conference today.

**Authorised for lodgement with NZX and ASX by:**

**John Cullity  
Chief Executive Officer  
EBOS Group Limited**



 **EBOS**  
GROUP LIMITED

# MACQUARIE AUSTRALIA CONFERENCE

John Cullity – Chief Executive Officer

5 May 2020



# DISCLAIMER

The information in this presentation was prepared by EBOS Group Ltd (EBOS) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or reliability of the information. In addition, neither EBOS nor any of its subsidiaries, directors, employees, shareholders nor any other person shall have liability whatsoever to any person for any loss (including, without limitation, arising from any fault or negligence) arising from this presentation or any information supplied in connection with it.

This presentation may contain forward-looking statements and projections. These reflect EBOS' current expectations, based on what it thinks are reasonable assumptions. EBOS gives no warranty or representation as to its future financial performance or any future matter. Except as required by law or NZX or ASX listing rules, EBOS is not obliged to update this presentation after its release, even if things change materially. This presentation does not constitute financial advice. Further, this presentation is not and should not be construed as an offer to sell or a solicitation of an offer to buy EBOS securities and may not be relied upon in connection with any purchase of EBOS securities.

This presentation contains a number of non-GAAP financial measures, including Gross Profit, Gross Operating Revenue, EBIT, EBITA, EBITDA, Underlying EBITDA, NPAT, Underlying NPAT, Underlying Earnings per Share, Free Cash Flow, Interest cover, Net Debt and Return on Capital Employed. Because they are not defined by GAAP or IFRS, EBOS' calculation of these measures may differ from similarly titled measures presented by other companies and they should not be considered in isolation from, or construed as an alternative to, other financial measures determined in accordance with GAAP. Although EBOS believes they provide useful information in measuring the financial performance and condition of EBOS' business, readers are cautioned not to place undue reliance on these non-GAAP financial measures.

The information contained in this presentation should be considered in conjunction with the consolidated financial statements for the period ended 31 December 2019.

**All currency amounts are in Australian dollars unless stated otherwise.**

# COMPANY SNAPSHOT

EBOS Group is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading marketer and distributor of recognised consumer products and animal care brands

## First Half FY20 Highlights

### Revenue

\$4.4 billion up 25.2%

NZ\$3.6 billion

market capitalisation<sup>1</sup>  
(NZX and ASX dual listed)

### Underlying EBITDA

\$149.0 million up 13.4%

3,700+  
employees

### Underlying NPAT

\$84.2 million up 15.8%

84% Healthcare  
16% Animal Care

H1 FY20 EBITDA Split

### Underlying EPS

52.2c up 9.1%

22.6% annualised  
Shareholder return<sup>2</sup>

last 5 calendar years



All currency amounts are in Australian dollars unless stated otherwise. Underlying results exclude the impact of IFRS 16 Leases and net one-off costs

Note 1: as at 1 May 2020

Note 2: Calculated as total shareholder return for the 5 years to 1 May 2020, assuming dividends are reinvested

# SHARE PRICE PERFORMANCE

EBOS share price appreciation of 134% over five years



Source: Nasdaq (rebased to EBO.NZX for comparative purposes)  
Date range: 5 years to 1 May 2020

# GROUP OVERVIEW

EBOS is a diversified health care and animal care products group with leading brands

	Description	Brands
 <b>Healthcare</b>	<b>Community Pharmacy – Wholesale</b> <ul style="list-style-type: none"> <li>Pharmaceutical wholesaler to ~3500+ pharmacies in Australia &amp; New Zealand</li> </ul>	   <small>PHARMACY WHOLESALERS RUSSELLS</small>
	<b>Community Pharmacy – Retail</b> <ul style="list-style-type: none"> <li>~1300+ Australian pharmacies in our TerryWhite Chemmart and other retail banner networks</li> </ul>	   
	<b>Institutional Healthcare</b> <ul style="list-style-type: none"> <li>Wholesaler to ~7000+ hospitals, aged care facilities and GPs in Australia &amp; New Zealand</li> <li>Entry position in medical devices distribution</li> </ul>	    
	<b>Contract Logistics</b> <ul style="list-style-type: none"> <li>3PL/4PL contract logistics provider to ethical, consumer health (OTC) and medical device manufacturers in Australia &amp; New Zealand, along with clinical trial work</li> </ul>	
	<b>Consumer Products</b> <ul style="list-style-type: none"> <li>Marketer and distributor of specialist brands with 2000+ SKUs distributed through pharmacy, grocery and other channels</li> </ul>	   
 <b>Animal Care</b>	<b>Products &amp; Brands</b> <ul style="list-style-type: none"> <li>Marketer of pet food and pet treats brands sold through specialty, grocery and online channels in Australia &amp; New Zealand</li> </ul>	  
	<b>Vet Wholesale</b> <ul style="list-style-type: none"> <li>Veterinary products wholesaler to ~2000+ vets in Australia</li> </ul>	
	<b>Retail</b> <ul style="list-style-type: none"> <li>Pet retail stores and vet clinics in New Zealand with over 50 locations</li> </ul>	

# SCALE & LEADING MARKET POSITIONS

EBOS generates >A\$7bn<sup>1</sup> of revenue and has leading market positions across Australia and New Zealand



	Australia	New Zealand	
<b>Healthcare</b> 	Community Pharmacy – Wholesale	• #1 wholesaler to pharmacies	• #1 wholesaler to pharmacies
	Community Pharmacy - Retail	• One of the largest aggregated retail banner networks	
	Institutional Healthcare	• #1 wholesaler to hospitals	• #1 wholesaler to hospitals
	Contract Logistics	• Growing market position	• #1 distributor for ethical, consumer health and medical device manufacturers
<b>Animal Care</b> 	Products & Brands	• #1 pet food and pet treats brands <sup>3</sup>	• #1 pet treats and #2 pet food brands <sup>3</sup>
	Vet Wholesale	• #2 veterinary wholesaler	
	Retail		• #1 pet retail store

*~90% of group revenue is generated by businesses with the #1 market position<sup>2</sup>*

Note 1: Based on FY19 revenue


Note 2: Based on 1H20 financials

Note 3: Pet food market share is for the pet specialty store channel; pet treats market share is for the grocery channel

# GROUP DIVERSITY


EBOS is a diverse group across sectors and geographies and operates across the value chain

Sector and segment mix<sup>1</sup>



- Health Care
- Pharmacy (Wholesale and retail)
- Animal Care
- Institutional Healthcare
- Contract Logistics
- Consumer Products

Healthcare geographic mix<sup>2</sup>



- Australia
- New Zealand

*Our diversity has supported stability in our earnings growth and cash flow generation*

Note 1: Based on 1H20 Gross Operating Revenue

Note 2: Based on Healthcare 1H20 revenue

# H1 FY20 HIGHLIGHTS

Group revenue increased by 25.2% in H1 FY20 evidencing the strength of our portfolio of businesses with a substantial uplift in Pharmacy Wholesale and strong performances from TerryWhite Chemmart, Institutional Healthcare and Healthcare Logistics




The Australian wholesale business demonstrated its leading competitive position with a significant increase in revenues and profit.



The acquisition of LMT/NS for \$34m signals EBOS' entry into the A\$8b Australian and New Zealand medical device sector creating a new platform of growth for the Group.



We have reignited the growth of TerryWhite Chemmart (TWC), one of Australia's leading community pharmacy networks. The TWC network delivered 5.7% sales growth on the prior period and added 16 new stores to the network.




Strong performances from our Institutional Healthcare business, Contract Logistics business and Animal Care segment.



Successful commencement of the Chemist Warehouse Group contract from 1 July 2019.



Strong balance sheet and liquidity with a Net Debt : EBITDA ratio of 1.41x<sup>1</sup>.




FY20 guidance is for a significant increase in earnings in the current financial year.


# FINANCIAL PERFORMANCE

EBOS has delivered significant shareholder value with a strong ROCE and consistent growth

### EBITDA<sup>1</sup> (A\$m)




### Dividends Per Share<sup>1</sup> (NZ\$ cents)



### Earnings Per Share<sup>1</sup> (A\$ cents)



### Return on Capital Employed (ROCE)



Note 1: Underlying data presented for EBITDA, DPS and EPS

# STRATEGIC APPROACH

Our Healthcare and Animal Care strategic focus is centred on:

## Leading Market Positions

- Establish and further strengthen our leading market positions and maximise opportunities across our diverse range of businesses.

## Investing for Growth

- **Capex:** Maintain and extend our market leadership through continued investment in our lowest-cost-per-unit distribution network, allowing us to deliver optimal customer outcomes.
- **Acquisitions:** Successful track record of acquisitions in core and adjacent markets to provide incremental growth (completed 21 acquisitions since 2000).

## Disciplined Capital Management

- Cash generation to drive further investment and pay dividends of not less than 60% of Net Profit After Tax.
- Strategic focus on Return on Capital Employed (ROCE) of at least 15%.
- Industry leading cash conversion of 16 days<sup>1</sup>.

*We focus on delivering profitable growth and superior returns*

# INVESTING FOR GROWTH AND RETURNS

EBOS has a proven track record of value accretive investments

## Investment strategy

- Acquire businesses aligned to our strategy
- Invest in automated distribution network solutions to extend our market leadership
- Disciplined adherence to investment criteria

## Shareholder outcomes

- EPS growth
- DPS growth
- Strong return on capital



# STRATEGIC FOCUS AREAS FOR GROWTH

With the right mix of businesses that deliver consistency in our performance and with a strong balance sheet, we aim to:



Continue to execute on both organic initiatives and strategic value accretive acquisitions.



Leverage our position as the lowest cost pharmaceutical wholesaler.



Continue to invest in the expansion of the TWC store network.



Expand on our initial investments into the Medical Devices sector.



Build and acquire trusted brands that consumers value in Animal Care and Consumer Health.



Expand our brands into Asian markets.

# COVID-19 MARKET UPDATE

**On 21 April, EBOS advised of strong trading conditions to 31 March 2020 and confirmed its balance sheet strength**

## Trading Conditions

- Our wholesale, distribution and retail Healthcare businesses are essential services and critical in ensuring continued and stable supply of healthcare, medical and pharmaceutical products to the community.
- Since our H1 FY20 results we have seen positive momentum across our businesses through to the end of the 3<sup>rd</sup> quarter ended 31 March 2020. Both our Healthcare and Animal Care segments generated solid revenue growth as a result of an increase in demand.
  - During the 3<sup>rd</sup> quarter, the Healthcare segment experienced unprecedented levels of demand.
  - Significant investment over recent years in our Healthcare distribution network positioned us well to meet the increased demand from customers.
- COVID-19 may affect different areas of our diversified Healthcare and Animal Care business in different ways during the next period of uncertain consumer demand.

## Liquidity

- Approximately A\$200m of bank debt and working capital facilities was refinanced in March 2020 and, due to strong bank demand, the facility was upsized to A\$250m.
- We have a strong balance sheet and liquidity position to meet ongoing business needs and our growth strategy.



Children's  
Medicine

Pain Relief

\$15.99

\$13.99

TerryWhite  
Chalmers

TerryWh

RESCRIPTION

Did you know?

PROFESSIONAL

3+

EBOS  
GROUP LIMITED

\$19.95

QUESTIONS



# APPENDIX

# H1 FY20 FINANCIAL PERFORMANCE

A\$m	H1 FY20	H1 FY19	Var\$	Var%
<b>Underlying Results <sup>1</sup></b>				
Revenue	4,376.1	3,496.5	879.6	25.2%
Gross Operating Revenue	449.4	404.8	44.6	11.0%
<b>EBITDA</b>	<b>149.0</b>	<b>131.4</b>	<b>17.6</b>	<b>13.4%</b>
<b>Net Profit after Tax</b>	<b>84.2</b>	<b>72.7</b>	<b>11.5</b>	<b>15.8%</b>
Earnings per share - cps	52.2c	47.8c	4.4c	9.1%
Net Debt : EBITDA	1.41x	2.16x		
<b>Statutory Results</b>				
Revenue	4,376.1	3,496.5	879.6	25.2%
EBITDA	167.2	122.6	44.6	36.4%
EBIT	131.4	107.3	24.0	22.4%
Net Profit After Tax	81.7	67.0	14.6	21.8%
Earnings per share - cps	50.6c	44.1c	6.5c	14.8%

- Significant revenue increase of 25.2% primarily due to growth in Pharmacy Wholesale, TerryWhite Chemmart, Institutional Healthcare and Contract Logistics.
- Underlying EBITDA increase of \$17.6m or 13.4%:
  - Healthcare up 16.3%.
  - Animal Care up 5.7%.
- Underlying NPAT and Underlying EPS increases of 15.8% and 9.1%, respectively.

Note 1: Underlying results exclude the impact of IFRS 16 Leases and net one-off costs.


# CASH FLOW

A\$m	H1 FY20	H1 FY19	Var\$	Var%
<b>Statutory Cash Flow including IFRS 16 Leases</b>				
<b>EBITDA</b>	<b>167.2</b>	<b>122.6</b>	<b>44.6</b>	<b>36.4%</b>
Net interest paid	(15.4)	(12.4)	(3.1)	
Tax paid	(32.6)	(25.7)	(6.9)	
Net working capital and other movements	(45.0)	(44.3)	(0.7)	
<b>Cash from Operating activities</b>	<b>74.2</b>	<b>40.3</b>	<b>34.0</b>	<b>84.4%</b>
Capital expenditure (net)	(13.7)	(16.9)	3.2	
<b>Free Cash Flow</b>	<b>60.5</b>	<b>23.3</b>	<b>37.2</b>	<b>159.5%</b>


- Statutory Operating Cash Flow of \$74.2m is above last year by \$34.0m due to the significant increase in earnings and continued working capital management.

# NET DEBT AND MATURITY PROFILE

## Net Debt and Net Debt : EBITDA ratio <sup>1</sup>



## Debt Maturity Profile – facility limits <sup>1</sup>



- Net Debt<sup>1</sup> of \$392m at December 2019, with a Net Debt : EBITDA<sup>1</sup> ratio of 1.41x (1.41x at June 2019).
- Current gearing continues to provide approximately \$300m – \$350m headroom for future acquisitions.
- Bank covenants have been amended to adopt a frozen gap approach with respect to IFRS 16 Leases.

- At 31 December 2019, gross drawn debt<sup>1</sup> was \$666m or 64% of total facility limits.
- At 31 December 2019, the weighted average maturity of our combined term debt and securitisation facilities is 1.9 years with actions underway to extend the term of our debt facilities by 30 June 2020.

Note 1: Debt and the Net Debt : EBITDA ratio excludes the impacts of IFRS 16 Leases.

# HEALTHCARE SEGMENT




## Significant growth in Australia from a strong underlying trading performance

A\$m	H1 FY20	H1 FY19	Var\$	Var%
Revenue	4,165.5	3,304.2	861.3	26.1%
Underlying EBITDA <sup>1</sup>	131.1	112.7	18.4	16.3%
Underlying EBITDA%	3.2%	3.4%		

- Healthcare growth in revenue of 26.1% and Underlying EBITDA of 16.3% was driven by the performances of our Community Pharmacy, TWC, Institutional Healthcare and Contract Logistics businesses.
- Productivity improvements in wholesale operations due to higher volumes across our sites and the new Brisbane facility.
- Strong performance of our retail brands, particularly TWC. We welcomed 16 new stores to our TWC network.
- The new 25,000m<sup>2</sup> facility in Sydney and further expansion in Auckland has created further growth in both countries.
- Consumer Products performance was affected by softer overseas demand, reflective of the changes which have impacted the daigou export channel.

Underlying EBITDA and Underlying EBITDA %



Note 1: Underlying results exclude the impact of IFRS 16 Leases and net one-off costs.

# ANIMAL CARE SEGMENT




Strong Revenue and Underlying EBITDA performance reflecting continued growth in our key brands

A\$m	H1 FY20	H1 FY19	Var\$	Var%
Revenue	210.6	192.3	18.3	9.5%
Underlying EBITDA	25.7	24.3	1.4	5.7%
Underlying EBITDA%	12.2%	12.6%		

- Revenue growth of \$18.3m, or 9.5%, due to the continued excellent performance of our branded products portfolio and higher vet wholesale volumes.
- Our key brands Black Hawk and Vitapet recorded strong uplifts in revenue both growing their market share.
  - Black Hawk** sales grew 9.7% due to strong consumer support, continued investment in marketing and maintaining its price value proposition.
  - Vitapet's** strong sales growth of 14.7% is due to a strong new product pipeline, marketing support and improved ranging in the Australian grocery channel.

Underlying EBITDA and Underlying EBITDA %





[www.ebosgroup.com](http://www.ebosgroup.com)

